Castleman's disease: Difference between revisions

	Castleman's disease Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Castleman's disease from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Castleman's disease On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Castleman's disease All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Castleman's disease
CDC on Castleman's disease
Castleman's disease in the news
Blogs on Castleman's disease
Directions to Hospitals Treating Castleman's disease
Risk calculators and risk factors for Castleman's disease

← Older edit

VisualWikitext

Latest revision as of 14:28, 21 September 2012

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Synonyms and keywords: Angiofollicular lymph node hyperplasia; lymphoid hamartoma; angiofollicular ganglionic hyperplasia

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Castleman's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Treatment

Case Studies

Case #1 de:Morbus Castleman

Template:WS

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{SI}}
+{{DiseaseDisorder infobox |
+ Name = Castleman's Disease |
+ ICD10 = {{ICD10|D|36|0|}} |
+ UMLS = C0017531 - C2931179 |
+ MeshID =  D005871 |
+ MedDRA = 10050251 |
+ SNOMED CT = 207036003 - 238809002
+}}
+{{Castleman's disease}}
 {{CMG}}; {{AE}} {{RT}}
-{{SK}}  Angiofollicular lymph node hyperplasia; lymphoid hamartoma
+{{SK}}  Angiofollicular lymph node hyperplasia; lymphoid hamartoma; angiofollicular ganglionic hyperplasia
-==Overview==
+==[[Castleman's disease overview|Overview]]==
-'''Castleman's disease''' is a rare disorder characterized by non-cancerous growths (tumors) that may develop in the lymph node tissue throughout the body. It involves  hyperproliferation of certain [[B cell]]s that often produce cytokines.
+==[[Castleman's disease historical perspective|Historical Perspective]]==
-There are several variants of Castleman's disease.  About 50% of '''Multicentric Castleman's disease''' (MCD) is caused by ''[[Kaposi's sarcoma-associated herpesvirus]]'' (KSHV), a gammaherpesvirus that is also the cause of [[Kaposi's sarcoma]] and [[primary effusion lymphoma]], while the remainder of MCD are of unknown cause.   The form of MCD most closely associated with KSHV is the plasmacytic form of Castleman's disease while another pathologic form, the hyaline-vascular form, is generally negative for this virus.   In all cases, Castleman's disease is likely due to hypersecretion of the cytokine [[Interleukin 6|IL-6]].  In KSHV positive tumors, this is most likely due to expression of the a virus-encoded cytokine, vIL-6, while KSHV negative tumors appear to be the result of over secretion of human IL-6.
+==[[Castleman's disease classification|Classification]]==
-==Symptoms==
+==[[Castleman's disease pathophysiology|Pathophysiology]]==
-The most common 'B Symptoms' of MCD are high [[fevers]], [[anemia]], [[weight loss]], [[loss of appetite]], and [[low white blood cell counts]], which may to be due to the overproduction of [[interleukin 6]]. Symptomatically, therefore, MCD can be difficult to diagnose and even in the case of a lymph-node biopsy a conclusive diagnosis remains problematic.
-==Treatment==
+==[[Castleman's disease causes|Causes]]==
-There is no standard therapy for Castleman's disease at the moment; prior to 1996 MCD has carried a poor prognosis of about 2 years, due to [[autoimmune hemolytic anemia]], [[non-Hodgkin's lymphoma]] which may arise as a result of proliferation of infected cells.  The timing of diagnosis, with particular attention to the difficulty of determining the cause of B symptoms without a CT scan and lymph node biopsy, may impact significantly on the prognosis and risk of death. Left untreated, MCD usually gets worse and becomes increasingly difficult and unresponsive to current treatment regimens. Recent work with HIV-positive patients with KSHV-related MCD suggests that treatment with the antiherpesvirus drug [[ganciclovir]] or the antiCD20 B cell [[monoclonal antibody]], [[rituximab]], may markedly improve outcome. These drugs target and kill B cells using the CD20 marker of a patient's antibody. Since B cells are required for the production of white blood cells, the body's immune response is weakened whilst on treatment and the risk of further viral or bacterial infection is increased. Due to the uncommon nature of the condition there are not many large scale research studies from which standardized approaches to therapy may be drawn, and the extant case studies of individuals or small cohorts should be read with caution. As with many diseases, the patient's age, physical state and previous medical history with respect to infections may impact on the disease progression and outcome.
+==[[Castleman's disease differential diagnosis|Differentiating Castleman's disease from other Diseases]]==
+==[[Castleman's disease epidemiology and demographics|Epidemiology and Demographics]]==
+==[[Castleman's disease risk factors|Risk Factors]]==
+==[[Castleman's disease natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
+==Diagnosis==
-Prior to 1996 and before HAART triple therapy was introduced for HIV positive patients, the prognosis of Kaposi's Sarcoma was about 18 months. Today, the prognosis for Kaposi's is generally very good and people with HIV KS can expect to have a successful outcome with current treatment regimens. This indicates that although the prognosis for MCD is two to three years, it is still retrospectively better than Kaposi's was historically, which is now a treatable and manageable condition.
+[[Castleman's disease history and symptoms|History and Symptoms ]] | [[ Castleman's disease physical examination|Physical Examination]] | [[Castleman's disease laboratory findings|Laboratory Findings]] | [[ Castleman's disease chest x ray|Chest X Ray]] | [[Castleman's disease CT|CT]] | [[Castleman's disease MRI|MRI]] | [[Castleman's disease ultrasound|Ultrasound]] | [[Castleman's disease other imaging findings|Other Imaging Findings]] | [[Castleman's disease other diagnostic studies|Other Diagnostic Studies]]
-==References==
+==Treatment==
-{{reflist|2}}
+[[Castleman's disease medical therapy|Medical Therapy]] | [[Castleman's disease surgery |Surgery]] | [[Castleman's disease primary prevention|Primary Prevention]] | [[Castleman's disease secondary prevention|Secondary Prevention]] | [[Castleman's disease cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] |  [[Castleman's disease future or investigational therapies|Future or Investigational Therapies]]
-*  Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little RF, Tosato G. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 2001;97(7):2173-6.
-*  Yarchoan R, Little RF. Immunosuppression-related malignancies. In: DeVita Jr. VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology 6th Edition. Philadelphia: Lippincott Williams and Wilkins; 2001:2575-97.
+==Case Studies==
+[[Castleman's disease case study one|Case #1]]
 [[Category:Disease]]

Castleman's disease: Difference between revisions

Latest revision as of 14:28, 21 September 2012

Diagnosis

Treatment

Case Studies

Navigation menu

Search